In a report released on March 21, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), with a ...

Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG (NOVN – Research Report) on March 17 and set a price target of ...

Independent Advisor Alliance raised its holdings in Novartis AG (NYSE:NVS – Free Report) by 23.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC.

Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...

Connor Clark & Lunn Investment Management Ltd. lowered its position in Novartis AG (NYSE:NVS – Free Report) by 95.6% in the 4th quarter, according to the company in its most recent Form 13F filing ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other undervalued stocks. On March 5th, BBC reported that the US stock market had fallen after the ...

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

February 25, 2025 Sandoz family foundation offers $3 billion worth of Novartis shares Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares ...

The development of advanced radiotherapy technologies has, in turn, resulted in an increased complexity of operations. Also, a high level of accuracy is needed at every step of the process to achieve ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...